









Markets
/
Stocks
/
nasdaq-bcyc
/

Bicycle Therapeutics PLC

BCYC

7.160USD

+0.240+3.47%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

495.86MMarket Cap

LossP/E TTM



Bicycle Therapeutics PLC

7.160

+0.240+3.47%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

108 / 506

Overall Ranking

219 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 14 analysts

Buy

Current Rating

24.417

Target Price

+252.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 143.90% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 35.27M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 49.96.

Overvalued

The company’s latest PE is -2.04, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 46.21M shares, decreasing 24.64% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 1.77M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 6.43, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.92M, representing a year-over-year decrease of 68.81%, while its net profit experienced a year-over-year decrease of 98.31%.

Score

Industry at a Glance

Previous score

6.43

Change



Financials

9.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.49

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.97, which is 98.11% below the recent high of -3.90 and -200.12% above the recent low of -5.90.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 108/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.14, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Bicycle Therapeutics PLC is 25.50, with a high of 44.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.14

Change

Support & Resistance

No Data

Analyst Rating

Based on 14 analysts

Buy

Current Rating

24.417

Target Price

+252.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Bicycle Therapeutics PLC

BCYC

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 4.94, which is lower than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 7.46 and the support level at 6.57, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.94

Change

0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.057

Neutral

RSI(14)

48.917

Neutral

STOCH(KDJ)(9,3,3)

49.490

Buy

ATR(14)

0.393

Low Volatility

CCI(14)

18.311

Neutral

Williams %R

54.062

Neutral

TRIX(12,20)

-0.318

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.992

Buy

MA10

7.026

Buy

MA20

7.065

Buy

MA50

7.591

Sell

MA100

7.828

Sell

MA200

10.012

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 95.43%, representing a quarter-over-quarter decrease of 1.07%. The largest institutional shareholder is Steven Cohen, holding a total of 1.77M shares, representing 3.55% of shares outstanding, with 62.88% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

10.89M

-0.08%

Forbion Capital Partners

3.45M

Armistice Capital LLC

2.67M

+21.68%

Westfield Capital Management Company, L.P.

2.66M

+1.80%

Invus Public Equities Advisors, LLC

1.81M

-1.45%

Point72 Asset Management, L.P.

Star Investors

3.69M

-18.94%

T. Rowe Price Associates, Inc.

Star Investors

1.54M

-3.06%

Candriam Luxembourg S.A.

1.21M

-1.69%

Long Focus Capital Management LLC

1.29M

+138.22%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.04, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.46. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.